Reckitt Benckiser to spin out US pharma arm


Consumer health firm Reckitt–Benckiser plans to spin off its US pharmaceutical division, whose primary product is heroin-substitute Suboxone (buprenorphine and naloxone) for treating addiction.

Suboxone’s patent protection has expired, and generic competition is eroding the drug’s sales and market share. With Reckitt increasingly focusing on over-the-counter and consumer products, the company has decided that the best option is to divest the business as a separate company, specialising in addiction. Reckitt expects the spin-off to be completed in the next 12 months.


Related Content

Reckitt steps into Schiff deal

19 November 2012 Business

news image

Higher bid could sink Bayer's $1.2bn attempt to buy vitamins and nutritional supplements company

The pain killer

13 November 2013 Jobs Profile (Personal)

news image

Life is pretty painless working in Reckitt Benckiser's Nurofen team, Sarah Houlton learns

Most Read

Mystery of coloured water droplets that chase and repel each other solved

19 March 2015 Research

news image

Discovery could herald sprays that hoover up dirt and keep solar panels clean

Simple cooking changes make healthier rice

23 March 2015 Research

news image

Adding oil to water, cooling and reheating rice makes fibre-like resistant starch, reducing calories

Most Commented

Worrying molecule found in bottled water

9 September 2013 Research

news image

Analysis finds a new endocrine disrupting chemical in bottled water

Impatient chemistry

28 February 2014 Last Retort

news image

Is the pressure to publish making chemists cut corners?